Weighted Average Number of Shares Outstanding, Diluted of INTERCEPT PHARMACEUTICALS, INC. from 30 Jun 2013 to 30 Sep 2023

Taxonomy & unit
us-gaap: shares
Description
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Summary
INTERCEPT PHARMACEUTICALS, INC. quarterly and annual Weighted Average Number of Shares Outstanding, Diluted in shares history and change rate from 30 Jun 2013 to 30 Sep 2023.
  • INTERCEPT PHARMACEUTICALS, INC. Weighted Average Number of Shares Outstanding, Diluted for the quarter ending 30 Sep 2023 was 41,792,000, a 22% increase year-over-year.
  • INTERCEPT PHARMACEUTICALS, INC. annual Weighted Average Number of Shares Outstanding, Diluted for 2022 was 33,837,000, a 6.1% increase from 2021.
  • INTERCEPT PHARMACEUTICALS, INC. annual Weighted Average Number of Shares Outstanding, Diluted for 2021 was 31,894,000, a 3.3% decline from 2020.
  • INTERCEPT PHARMACEUTICALS, INC. annual Weighted Average Number of Shares Outstanding, Diluted for 2020 was 32,970,000, a 4.2% increase from 2019.
Source SEC data
View on sec.gov
Weighted Average Number of Shares Outstanding, Diluted, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Diluted, Annual (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Annual Change (%)

INTERCEPT PHARMACEUTICALS, INC. Quarterly Weighted Average Number of Shares Outstanding, Diluted (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2023 41,792,000 +7,499,000 +22% 01 Jul 2023 30 Sep 2023 10-Q 06 Nov 2023 2023 Q3
Q2 2023 41,731,000 +11,984,000 +40% 01 Apr 2023 30 Jun 2023 10-Q 02 Aug 2023 2023 Q2
Q1 2023 41,670,000 +11,974,000 +40% 01 Jan 2023 31 Mar 2023 10-Q 27 Apr 2023 2023 Q1
Q4 2022 33,837,000 +1,943,000 +6.1% 01 Oct 2022 31 Dec 2022 10-K 02 Mar 2023 2022 FY
Q3 2022 34,293,000 +2,557,000 +8.1% 01 Jul 2022 30 Sep 2022 10-Q 06 Nov 2023 2023 Q3
Q2 2022 29,747,000 -3,432,000 -10% 01 Apr 2022 30 Jun 2022 10-Q 02 Aug 2023 2023 Q2
Q1 2022 29,696,000 -3,443,000 -10% 01 Jan 2022 31 Mar 2022 10-Q 27 Apr 2023 2023 Q1
Q4 2021 31,894,000 01 Oct 2021 31 Dec 2021 10-K 02 Mar 2023 2022 FY
Q3 2021 31,736,000 -1,253,000 -3.8% 01 Jul 2021 30 Sep 2021 10-Q 01 Nov 2022 2022 Q3
Q2 2021 33,179,000 01 Apr 2021 30 Jun 2021 10-Q 03 Aug 2022 2022 Q2
Q1 2021 33,139,000 01 Jan 2021 31 Mar 2021 10-Q 06 May 2022 2022 Q1
Q3 2020 32,989,000 01 Jul 2020 30 Sep 2020 10-Q 03 Nov 2021 2021 Q3
Q2 2015 24,014,092 +1,809,158 +8.1% 01 Apr 2015 30 Jun 2015 10-Q 07 Aug 2015 2015 Q2
Q2 2014 22,204,934 +5,234,415 +31% 01 Apr 2014 30 Jun 2014 10-Q 07 Aug 2015 2015 Q2
Q2 2013 16,970,519 01 Apr 2013 30 Jun 2013 10-Q 11 Aug 2014 2014 Q2

INTERCEPT PHARMACEUTICALS, INC. Annual Weighted Average Number of Shares Outstanding, Diluted (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2022 33,837,000 +1,943,000 +6.1% 01 Jan 2022 31 Dec 2022 10-K 02 Mar 2023 2022 FY
2021 31,894,000 -1,076,000 -3.3% 01 Jan 2021 31 Dec 2021 10-K 02 Mar 2023 2022 FY
2020 32,970,000 +1,316,000 +4.2% 01 Jan 2020 31 Dec 2020 10-K 02 Mar 2023 2022 FY
2019 31,654,000 01 Jan 2019 31 Dec 2019 10-K 02 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.